16 results on '"Nestle SA"'
Search Results
2. PACKAGING BAG
- Author
-
NESTLE SA
- Subjects
B65D30/22 - Abstract
The invention relates to a packaging bag (1) for accommodating semifinished foodstuff products, having an outer enclosure made of packaging material sheets which are connected to one another by border seams along the bag edges, it being the case that the bag (1) is open along at least one of its edges (5) for the filling operation and, following the filling operation, can be closed by virtue of said open edge (5) being sealed, it being the case that the bag (1) has an inner separating sheet (6) which has a free edge (9) and further edges incorporated essentially into the bag border seams and which, prior to the filling operation, divides the bag interior into two open chambers (7, 8), and the inner separating sheet (6), in the region of its free edge 9, can be connected, by way of a first sealing seam, to the inner wall of one of the two packaging material sheets, a first closed chamber (7) being formed in the process, and then the open edge (5) of the bag (1) can be closed by a separate, second sealing seam, a second closed chamber been formed in the process.
3. SEALED FLEXIBLE CARTRIDGE
- Author
-
NESTLE SA, YOAKIM ALFRED, and MASEK PETR
- Subjects
B65D81/00 - Abstract
The present invention relates to a sealed flexible cartridge (1) , designed to be extracted under pressure, containing a substance for the preparation of a beverage, consisting of a first (3) and a second sheet (4) of circular, oval or polygonal shape which leave between them a space for the substance (2) and are welded together around their periphery (5), the first sheet (3) being made of a material chosen from filter paper, a non-woven and a semi-rigid material and the second sheet (4) being made of a material chosen from filter paper, a non-woven and a composite, in which the first sheet is such that it allows water at atmospheric pressure to pass through it or by piercing with a piercing means and the second sheet (4) is such that it allows water to pass through it only if an overpressure of between 0.1 and 3 bar is achieved during extraction from the said cartridge (1).
4. SHELF-STABLE CALCIUM FORTIFIED MILK AND DAIRY PRODUCTS
- Author
-
NESTLE SA, SHER ALEXANDER, MALLANGI CHANDRASEKHARA REDDY, JACOBSON MARK RANDOLPH, VADEHRA DARAM VIR, and WEDRAL ELAINE REGINA
- Subjects
A23C9/152 - Abstract
A calcium-fortified milk or dairy-based product comprising a calcium source and a food-grade polyphosphate having at least six phosphate groups.
5. DISPENSER WITH TWO-COMPARTMENT FLUID CONTAINER
- Author
-
NESTLE SA, CHENG PU-SHENG, CHRISMAN RANDALL C, GAVIE SHANNON, LANDRY WALTER, MCDONOUGH BRIAN J, MORRISON RANDALL L, and SCOVILLE EUGENE
- Subjects
B67D1/00 - Abstract
The present invention is related to a device and method for dispensing dual component liquids or concentrates packaged in separate containers to provide protection from effects such as oxidation and moisture loss. The liquids or concentrates can be dispensed through a pumping system, preferably including a peristaltic pump, mixed together, and optionally diluted with another liquid, such as water, to provide a consumable beverage. In addition, the device of the present invention can dispense liquids or concentrates having different viscosities, such that they are mixed together in the proper ratio.
6. NUTRITIONAL COMPOSITION
- Author
-
NESTLE SA, BERGER ALVIN, and CROZIER GAYLE
- Subjects
A23L1/30 ,A61K31/20 - Abstract
A nutritional or therapeutic composition for oral administration which comprises a naturally occurring precursor that is metabolised to a compound having anandamide activity for use as a medicament or nutritive product. In addition the invention includes a method of production of the composition, use of the composition in the manufacture of a nutritional composition for the treatment or prevention of a behavioural disorder; and a method of treatment or prevention of a behavioural disorder which comprises administering an effective amount of the composition. In a preferred embodiment the composition comprises a triacylglycerol having palmitate and arachidonate attached to its backbone wherein arachidonate is at the sn-1 and sn-2 positions.
7. LACTIC ACID BACTERIA STRAINS CAPABLE OF PREVENTING DIARRHOEA
- Author
-
NESTLE SA, RENIERO ROBERTO, BRUESSOW HARALD, ROCHAT FLORENCE, VON DER WEID THIERRY, and BLUM SPERISEN STEPHANIE
- Subjects
A61K35/74 ,A23C9/152 ,C12R1/225 ,C12N1/20 ,A23L1/29 - Abstract
The present invention pertains to novel microorganisms of the family Lactobacillaceae, especially to microorganisms of the genus Lactobacillus, that are useful in preventing or treating diarrhoea. In particular, the present invention relates to the use of said micro-organisms for the preparation of an ingestable support and to a composition containing the same.
8. Improved cocoa fermentation
- Author
-
NESTLE SA and GOLDEN HOPE PLANTATIONS BERHAD
- Subjects
A23G1/02 - Abstract
A method of treating fresh cocoa beans before fermentation which comprises passing the fresh beans dynamically through a depulper to remove up to 80% by weight of pulp based on the original weight of the pulp.
9. FROZEN CONFECTIONERY
- Author
-
NESTLE SA, SCHLEGEL MYRIAM, and WUERSCH PIERRE
- Subjects
A23G9/02 - Abstract
Frozen confectionery preserving its unctuosness and exhibiting reduced crystalline growth during a heat shock followed by refreezing, and comprising fat, sweetener, milk solids-not-fat and water, characterized in that the sum of the quantities of starch and milk solids-not-fat is between 2.5 and 18 % and in that the starch/milk solids-not-fat weight ratio is between 0.03 and 1.5. Process for manufacturing such a frozen confectionery.
10. BETA-GLUCANS FROM FILAMENTOUS FUNGI
- Author
-
NESTLE SA, FEDERICI FEDERICO, PETRUCCIOLI MAURIZIO, VAN DEN BROEK PETER, and STINGELE FRANCESCA
- Subjects
C12P19/04 ,C08B37/00 ,A61K31/716 ,C12P39/00 ,A23L1/29 - Abstract
A method of producing a beta-glucan; use of a non-pathogenic saprophytic filamentous fungus or composition comprising it for providing a beta-glucan and thereby improving food structure, texture, stability or a combination thereof; use of a non-pathogenic saprophytic filamentous fungus for providing a beta-glucan and thereby providing nutrition; and use of a fungus or composition comprising it in the manufacture of a medicament or nutritional composition for the prevention or treatment of an immune disorder, tumour or microbial infection.
11. MILK PRODUCT COMPRISING UNESTERIFIED STEROL
- Author
-
NESTLE SA, GROUX MICHEL JOHN ARTHUR, LESER MARTIN, and BERGER ALVIN
- Subjects
A61K31/575 ,A23L1/035 ,A23C9/152 ,A23L1/30 ,A23D9/007 ,A23C11/04 - Abstract
A composition comprises an unesterified sterol and a crystal modifier including sorbitan tristearate (STS). Prefered embodiments include an additional compound selected from the group consisting of sorbitan monostearate (SMS), one or more monoglycerides, one or more diglycerides, propyleneglycolmonosterate (PGMS) or a combination of two or more thereof. The composition is stable, has a long shelf life and sterols in the composition do not recrystalise. The composition can be used for lowering LDL cholesterol levels.
12. Method of conditioning for in vitro culture plant tissues
- Author
-
NESTLE SA
- Subjects
A01H4/00 ,C12M3/06 ,C12N5/04 - Abstract
Process for packaging vegetable tissue cultivated in vitro, in which, in a sterile receptacle, the cultivated tissue is placed between the faces of two solid supports impregnated with a liquid nutrient medium, the vegetable tissues being held fast to at least one of the faces of the supports by capillary action, and at least one of the other faces of the supports also being held fast to one of the walls of the receptacle by capillary action, and the tissue is stored.
13. Effect of the rheological properties of the liquid carrier on the in vitro swallowing of solid oral dosage forms
- Author
-
Anaïs Lavoisier, Marco Ramaioli, Sathyavageeswaran Shreeram, Michael Jedwab, Paris-Saclay Food and Bioproduct Engineering (SayFood), AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Nestlé Health Science Singapore, and Nestle SA
- Subjects
0106 biological sciences ,Pharmaceutical Science ,Capsules ,01 natural sciences ,Dosage form ,Viscosity ,0404 agricultural biotechnology ,Bolus (medicine) ,Rheology ,Swallowing ,010608 biotechnology ,Shear viscosity ,[SDV.IDA]Life Sciences [q-bio]/Food engineering ,Newtonian fluid ,Humans ,[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineering ,Capsule ,Carrier fluids ,Rheometry ,Chemistry ,digestive, oral, and skin physiology ,Relaxation time ,Dysphagia ,04 agricultural and veterinary sciences ,040401 food science ,Deglutition ,3. Good health ,Tablet ,Deglutition Disorders ,Tablets ,Food Science ,Biomedical engineering - Abstract
International audience; Solid Oral Dosage Forms (SODF) are the most popular oral drug delivery forms, but they can be difficult to swallow, especially for patients suffering from swallowing disorders. This study investigated the dynamics of different combinations of liquid carriers and SODF during the oral phase of swallowing using an in vitro model. The rheological properties of the carriers were characterized using shear and extensional rheometry, and their effect on bolus velocity, bolus shape, post-swallow residues, and SODF position within the bolus was evaluated. The latter has been identified as a novel and promising variable to discriminate between alternative formulations. When swallowed with water, capsules and tablets did not impact significantly the velocity of the bolus, but they lagged behind the liquid bolus, suggesting that low viscosity Newtonian fluids are not efficient carriers for SODF. Increasing the viscosity of the carrier at high shear rates improved the ability of the liquid to transport the SODF but also increased the amount of post-swallow residues. At equivalent shear viscosity, elastic and extensionalproperties of carriers influenced positively the position of the SODF in the bolus. Capsules and tablets were transported toward the front of these boluses, during the oral phase of swallowing, which is considered beneficial to avoid SODF sticking to the mucosa in the following stages of swallowing. Thin elastic liquids appear as an interesting option to promote safe swallowing of capsules and tablets. Clinical studies are, however, necessary to confirm this positive effect in healthy and dysphagic patients.
- Published
- 2021
- Full Text
- View/download PDF
14. Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood: A European Society for Paediatric Gastroenterology Hepatology and Nutrition Position Paper
- Author
-
Matjaž Homan, Nikhil Thapar, Mike Thomson, Christos Tzivinikos, Lissy de Ridder, Amani Mubarak, Emmanuel Mas, Marc A. Benninga, Ilse Broekaert, Corina Pienar, Jernej Dolinsek, Erasmo Miele, University Medical Center [Utrecht], Emma Children’s Hospital, University Hospital of Cologne [Cologne], University medical centre Maribor (UKC Maribor), Institut de Recherche en Santé Digestive (IRSD ), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), 'Federico II' University of Naples Medical School, Victor Babeş University of Medicine and Pharmacy (UMFT), Great Ormond Street Hospital for Children [London] (GOSH), Sheffield Children's NHS Foundation Trust, Al Jalila Children's Specialty Hospital, Eramus MC-Sophia Children’s Hospital, Partenaires INRAE, Nestle SA, Danone Nutricia, Mubarak, Amani, Benninga, Marc A, Broekaert, Ilse, Dolinsek, Jernej, Homan, Matjaž, Mas, Emmanuel, Miele, Erasmo, Pienar, Corina, Thapar, Nikhil, Thomson, Mike, Tzivinikos, Christo, de Ridder, Lissy, Paediatric Gastroenterology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ARD - Amsterdam Reproduction and Development, SEGUIN, Nathalie, and Pediatrics
- Subjects
medicine.medical_specialty ,MEDLINE ,[SPI.MAT] Engineering Sciences [physics]/Materials ,Asymptomatic ,[SPI.MAT]Engineering Sciences [physics]/Materials ,Eating ,03 medical and health sciences ,[SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics ,Electric Power Supplies ,Esophagus ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,030225 pediatrics ,Internal medicine ,medicine ,Humans ,endoscopy ,Child ,Intensive care medicine ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,medicine.diagnostic_test ,Impaction ,business.industry ,Gastroenterology ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,Guideline ,Hepatology ,Foreign Bodies ,foreign body ,esophageal perforation ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,3. Good health ,Endoscopy ,caustic ingestion ,[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition ,medicine.anatomical_structure ,pediatric ,Pediatrics, Perinatology and Child Health ,Position paper ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition - Abstract
International audience; Button batteries (BB) remain a health hazard to children as ingestion might lead to life-threatening complications, especially if the battery is impacted in the esophagus. Worldwide initiatives have been set up in order to prevent and also timely diagnose and manage BB ingestions. A European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) task force for BB ingestions has been founded, which aimed to contribute to reducing the health risks related to this event. It is important to focus on the European setting, next to other worldwide initiatives, to develop and implement effective management strategies. As one of the first initiatives of the ESPGHAN task force, this ESPGHAN position paper has been written. The literature is summarized, and prevention strategies are discussed focusing on some controversial topics. An algorithm for the diagnosis and management of BB ingestions is presented and compared to previous guidelines (NASPGHAN, National Poison Center). In agreement with earlier guidelines, immediate localization of the BB is important and in case of esophageal impaction, the BB should be removed instantly (preferably 12 hours after ingestion or time point of removal >12 hours after ingestion) and esophageal impaction the guideline suggests to perform a CT scan in order to evaluate for vascular injury before removing the battery. In delayed diagnosis, even if the battery has passed the esophagus, endoscopy to screen for esophageal damage and a CT scan to rule out vascular injury should be considered even in asymptomatic children. In asymptomatic patients with early diagnosis (
- Published
- 2021
- Full Text
- View/download PDF
15. Gut Microbiota Resilience: Definition, Link to Health and Strategies for Intervention
- Author
-
Shaillay Kumar Dogra, Joël Doré, Sami Damak, Nestlé Centre R & D [Lausanne, Suisse], MetaGenoPolis (MGP (US 1367)), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Nestle SA, and European Project: 788191,Homo.symbiosus
- Subjects
Microbiology (medical) ,media_common.quotation_subject ,Mini Review ,[SDV]Life Sciences [q-bio] ,lcsh:QR1-502 ,microbiome ,Disease ,Biology ,Gut flora ,Microbiology ,digestive system ,lcsh:Microbiology ,03 medical and health sciences ,fluids and secretions ,Intervention (counseling) ,Environmental health ,medicine ,Microbiome ,resilience ,030304 developmental biology ,media_common ,0303 health sciences ,030306 microbiology ,High fat diet ,health ,biology.organism_classification ,medicine.disease ,3. Good health ,stomatognathic diseases ,Psychological resilience ,Dysbiosis ,probiotic ,fiber - Abstract
International audience; The gut microbiota is a new frontier in health and disease. Not only many diseases are associated with perturbed microbiota, but an increasing number of studies point to a cause-effect relationship. Defining a healthy microbiota is not possible at the current state of our knowledge mostly because of high interindividual variability. A resilient microbiota could be used as surrogate for healthy microbiota. In addition, the gut microbiota is an "organ" with frontline exposure to environmental changes and insults. During the lifetime of an individual, it is exposed to challenges such as unhealthy diet, medications and infections. Impaired ability to bounce back to the pre-challenge baseline may lead to dysbiosis. It is therefore legitimate to postulate that maintaining a resilient microbiota may be important for health. Here we review the concept of resilience, what is known about the characteristics of a resilient microbiota, and how to assess microbiota resilience experimentally using a model of high fat diet challenge in humans. Interventions to maintain microbiota resilience can be guided by the knowledge of what microbial species or functions are perturbed by challenges, and designed to replace diminished species with probiotics, when available, or boost them with prebiotics. Fibers with multiple structures and composition can also be used to increase microbiota diversity, a characteristic of the microbiota that may be associated with resilience. We finally discuss some open questions and knowledge gaps.
- Full Text
- View/download PDF
16. Predictors of compliance with higher dose omega-3 fatty acid supplementation during pregnancy and implications for the risk of prematurity: exploratory analysis of the ORIP randomised trial.
- Author
-
Sullivan TR, Yelland LN, Gibson RA, Thakkar SK, Huang F, Best KP, Devaraj S, Zolezzi IS, and Makrides M
- Subjects
- Infant, Newborn, Female, Pregnancy, Humans, Capsules, Australia epidemiology, Dietary Supplements, Fatty Acids, Premature Birth epidemiology, Premature Birth prevention & control, Fatty Acids, Omega-3
- Abstract
Background: Intention-to-treat analyses of the Omega-3 to Reduce the Incidence of Prematurity (ORIP) trial found that omega-3 (n-3) fatty acid supplementation reduces the risk of prematurity in the subgroup of women with a singleton pregnancy and low n-3 status early in pregnancy, but not overall. However, results may have been influenced by less-than-optimal compliance., Objectives: To identify predictors of compliance with n-3 supplementation and determine treatment effects among compliers., Design: Exploratory analyses of a multicentre-blinded randomised trial., Setting: 6 tertiary care centres in Australia., Participants: 5328 singleton pregnancies., Interventions: Daily capsules containing 900 mg n-3 long-chain polyunsaturated fatty acids or vegetable oil, consumed from before 20 weeks gestation until 34 weeks gestation., Outcome Measures: Early preterm (<34 weeks gestation) and preterm birth (<37 weeks gestation). Women were considered compliant if they reported missing less than a third of their allocated capsules in the previous week during a mid-pregnancy appointment., Results: Among 2654 singleton pregnancies in the n-3 intervention group, 1727 (65%) were deemed compliant with supplementation. Maternal characteristics associated with compliance included age, years of full-time education, consuming alcohol but not smoking in the 3 months leading up to pregnancy, fewer previous births and taking dietary supplements at enrolment. Based on complier average causal effects, n-3 supplementation reduced the risk of preterm birth in compliers (relative risk=0.76; 95% CI 0.60 to 0.97), but not early preterm birth (relative risk=0.80; 95% CI 0.44 to 1.46). Consistent with intention-to-treat analyses, the lack of an overall effect on early preterm birth in compliers appeared to be due to beneficial effects in women with low n-3 status at enrolment but not women with replete status., Conclusions: Results in compliers were similar to those from intention-to-treat analyses, suggesting that non-compliance was not a major factor in explaining outcomes from the ORIP trial., Trial Registration Number: ACTRN12613001142729., Competing Interests: Competing interests: RAG has received supplies from Croda UK, prepared supplies for a trial for Efamol/Wassen UK and holds a patent (WO2013/10 40 25 A1) on stabilising and analysing fatty acids in a biologic sample stored on solid media, owned by Adelaide Research and Innovation, the University of Adelaide, and licensed to Xerion. SKT, FH, SD and ISZ are employees of Société des Produits Nestlé (SPN). MM has received supplies from Croda UK, and prepared supplies for a trial for Efamol/Wassen UK. The other authors do not have any competing interests., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.